Johnson & Johnson goes to trial its experimental Covid-19 vaccine
|Johnson & Johnson is reported to trial its experimental Covid-19 vaccine with 6,000 UK volunteers on a two-dose basis in a phase 3 trial
If successful, the next step would be to approach regulators for approval.
This is good news for markets in anticipation of a return to normality when the vaccines are distributed to the populations.
it follows last week's game-changer with the press release from Pfizer and BioNTech that said they had identified 94 cases of COVID-19 among 43,538 trial participants.
The threshold that the US Food and Drug Administration (FDA) says is required for a coronavirus vaccine to be approved for emergency use is just 50% and so far, the trial is proving a 90% success rate.
Meanwhile, there are still uncertainties as to the details about the nature of the infections the vaccine can protect against.
Market implications
Nevertheless, markets are pricing in a best-case scenario.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.